EISAI ANNOUNCES TOP-LINE PHASE III TRIAL RESULTS OF ERIBULIN IN PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER FOLLOWING AT LEAST TWO PRIOR REGIMENS

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) announced today top-line results of the investigational Phase III study (Study 302) of its in-house developed anticancer agent eribulin mesylate (“eribulin,” Brand name: Halaven®) in patients with advanced non-small cell lung cancer (NSCLC) that has progressed following two or more prior treatment regimens.

Study 302 was a global, multicenter, randomized, open-label Phase III trial comparing the efficacy and safety of eribulin with a single treatment of physician’s choice (TPC) consisting of either docetaxel, pemetrexed, gemcitabine or vinorelbine in 540 patients with advanced NSCLC and disease progression following at least two prior regimens for advanced disease, which included a platinum-based regimen.

9ìÍ “We know that NSCLC is a difficult to treat tumor type with no chemotherapy recognized as a standard treatment